Anthony Demaria, MD
Cardiovascular Disease · San Diego, CANPI 1124043948
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,200 of the $21,042 with a category attached, or 62.7%. Jenavalve Technology, Inc. accounts for 63.2% of it on its own, with 6 other manufacturers making up the rest. 2023 is the largest year on record at $15,719, more than ten times the $54 reported in 2019.
Across 11 payments — averaging $1912.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jenavalve Technology, Inc.$13K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$8K
- Novo Nordisk$128
- Akcea Therapeutics, Inc.$36
- Pfizer$33
- AstraZeneca$31
- plus $22 from 1 others
Across 23 payments — averaging $16,567 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$286K
- Akcea Therapeutics, Inc.$95K
What the payments were for
- Consulting fees$13,20063%
- Speaking & faculty fees$7,50036%
- Food & beverage$3422%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jenavalve Technology, Inc. | 2 | $13,292 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $7,500 |
| Novo Nordisk | 1 | $128 |
| Akcea Therapeutics, Inc. | 1 | $36 |
| Pfizer | 2 | $33 |
| AstraZeneca | 1 | $31 |
| Edwards Lifesciences | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JenaValve Pericardial TAVR System$13,200
- LifeVest$7,500
How this compares
$21,042 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 106 | $150,894 |
| Repatha SureclickEvolocumab | 56 | $43,920 |
| EntrestoSacubitril/Valsartan | 37 | $40,941 |
| XareltoRivaroxaban | 18 | $26,336 |
| JardianceEmpagliflozin | 18 | $24,432 |
| TrulicityDulaglutide | 11 | $12,690 |
| Candesartan Cilexetil | 35 | $3,290 |
| Atorvastatin Calcium | 206 | $2,617 |
| Rosuvastatin Calcium | 75 | $1,990 |
| Ezetimibe | 29 | $1,813 |
| Metoprolol Succinate | 66 | $1,516 |
| SotalolSotalol Hcl | 37 | $1,142 |
| Amlodipine Besylate | 121 | $920 |
| ClopidogrelClopidogrel Bisulfate | 46 | $821 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 22 | $671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $33 | $150,894106 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$278K
- Michael WilkinsonSan Diego$145K
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.